Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Translational control of gene expression
Sonenberg, N., Hershey, J. W. B., & Mathews, M. B. (2000) · Cold Spring Harbor Laboratory eBooks · Cited by 1,379
Translational control of gene expression
Hannig, E. M. (2001) · BioEssays · doi:10.1002/bies.1108 · Cited by 1,189
Role of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
Cited by
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
“Indeed, eIF4E promoted cell survival in in vivo mouse models of lymphoma by upregulating the translation of the anti-apoptotic protein myeloid leukaemia cell differentiation 1 (MCL1”
BackgroundA microRNA polycistron as a potential human oncogene
He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., et al. (2005) · Nature · doi:10.1038/nature03552 · Cited by 3,483
Self-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
“However, they found that overexpression of eIF4E (the binding partner of the mTORC1-regulated protein 4EBP1) avoided the rapamycin inhibition of growt”
BackgroundThe activation of Akt/PKB signaling pathway and cell survival
Song, G., Ouyang, G., & Bao, S. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00337.x · Cited by 1,888
DNA damage-induced cell death by apoptosis
Roos, W. P., & Kaina, B. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.007 · Cited by 1,500
Insulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Self-citationA transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
G1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
DNA damage and the balance between survival and death in cancer biology
Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189
Transcriptional regulation and transformation by Myc proteins
Adhikary, S., & Eilers, M. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1703 · Cited by 1,131
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F. P., & Grandaliano, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042831 · Cited by 990
Regulation of cap-dependent translation by eIF4E inhibitory proteins
Richter, J. D., & Sonenberg, N. (2005) · Nature · doi:10.1038/nature03205 · Cited by 970
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
“This inhibition of apoptosis by Akt has been characterized in many cancer cell systems [161–164].”
BackgroundMorita, M., Gravel, S.-P., Chénard, V., Sikström, K., Zheng, L., Alain, T., Gandin, V., Avizonis, D., Arguello, M., Zakaria, C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.001 · Cited by 842
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
Translational control in cancer
Silvera, D., Formenti, S. C., & Schneider, R. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2824 · Cited by 821
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention
Zhang, J., Grindley, J. C., Yin, T., Jayasinghe, S., He, X. C., Ross, J. T., Haug, J. S., Rupp, D., Porter-Westpfahl, K. S., Wiedemann, L. M., et al. (2006) · Nature · doi:10.1038/nature04747 · Cited by 817
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
Self-citationBhaskar, P. T., & Hay, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.03.020 · Cited by 798
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.012 · Cited by 740
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Greco, F., & Vicent, M. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.006 · Cited by 652
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Self-citationRecent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
mTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607
“Furthermore, two groups independently demonstrated that eIF4E promotes lymphomagenesis in cooperation with Myc in transgenic mice (Ruggero et al., 2004; Wendel et al., 2004).”
BackgroundSuppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB
Douma, S., van Laar, T., Zevenhoven, J., Meuwissen, R., van Garderen, E., & Peeper, D. S. (2004) · Nature · doi:10.1038/nature02765 · Cited by 607
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
Signaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591
Moerke, N. J., Aktas, H., Chen, H., Cantel, S., Reibarkh, M. Y., Fahmy, A., Gross, J. D., Degterev, A., Yuan, J., Chorev, M., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.046 · Cited by 572
mTOR coordinates protein synthesis, mitochondrial activity and proliferation
Morita, M., Gravel, S.-P., Hulea, L., Larsson, O., Pollak, M., St-Pierre, J., & Topisirovic, I. (2015) · Cell Cycle · doi:10.4161/15384101.2014.991572 · Cited by 552
An expanding role for mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.007 · Cited by 523
Signalling to translation: How signal transduction pathways control the protein synthetic machinery
Proud, C. G. (2007) · Biochemical Journal · doi:10.1042/bj20070024 · Cited by 520
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression
Furic, L., Rong, L., Larsson, O., Koumakpayi, I. H., Yoshida, K., Brueschke, A., Petroulakis, E., Robichaud, N., Pollak, M., Gaboury, L. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005320107 · Cited by 519
Ueda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S., & Fukunaga, R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6539-6549.2004 · Cited by 507
Wei, G., Twomey, D., Lamb, J., Schlis, K., Agarwal, J., Stam, R. W., Opferman, J. T., Sallan, S. E., den Boer, M. L., Pieters, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.006 · Cited by 509
A Genetic Screen for Candidate Tumor Suppressors Identifies REST
Westbrook, T. F., Martin, E. S., Schlabach, M. R., Leng, Y., Liang, A. C., Feng, B., Zhao, J. J., Roberts, T. M., Mandel, G., Hannon, G. J., et al. (2005) · Cell · doi:10.1016/j.cell.2005.03.033 · Cited by 489
Dissecting eIF4E action in tumorigenesis
Wendel, H.-G., Silva, R. L. A., Malina, A., Mills, J. R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., et al. (2007) · Genes & Development · doi:10.1101/gad.1604407 · Cited by 487
“We previously used adoptive transfer methods to show that eIF4E is a potent oncogene in the Eμ-Myc transgenic mouse lymphoma model, producing aggressive and drug resistant tumors (Wendel et al. 2004).”
BackgroundMethodSelf-citationBeuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
For better or for worse: the role of Pim oncogenes in tumorigenesis
Nawijn, M. C., Alendar, A., & Berns, A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2986 · Cited by 481
Manning, B. D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408161 · Cited by 476
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459
Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1
Sofer, A., Lei, K., Johannessen, C. M., & Ellisen, L. W. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5834-5845.2005 · Cited by 449
Amino acids and mTORC1: from lysosomes to disease
Efeyan, A., Zoncu, R., & Sabatini, D. M. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.05.007 · Cited by 436
“As part of mTORC1, mTOR activity drives translation of a subset of genes that activate the cell division programs and block the induction of programmed cell death [77,78].”
Ortega-Molina, A., Boss, I. W., Canela, A., Pan, H., Jiang, Y., Zhao, C., Jiang, M., Hu, D., Agirre, X., Niesvizky, I., et al. (2015) · Nature Medicine · doi:10.1038/nm.3943 · Cited by 436
Self-citationHsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434
FAK signaling in human cancer as a target for therapeutics
Lee, B. Y., Timpson, P., Horvath, L. G., & Daly, R. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.10.001 · Cited by 425
Stress granules, P-bodies and cancer
Anderson, P., Kedersha, N., & Ivanov, P. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.009 · Cited by 409
The survival kinases Akt and Pim as potential pharmacological targets
Amaravadi, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26273 · Cited by 408
The roles of microRNA in cancer and apoptosis
Lynam‐Lennon, N., Maher, S. G., & Reynolds, J. V. (2009) · Biological Reviews · doi:10.1111/j.1469-185x.2008.00061.x · Cited by 407
Targeting mammalian target of rapamycin (mTOR) for health and diseases
Tsang, C. K., Qi, H., Liu, L. F., & Zheng, X. F. S. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.008 · Cited by 406
She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400
NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
Chio, I. I. C., Jafarnejad, S. M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Öhlund, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.056 · Cited by 378
“…that deregulate mRNA translation are common events in human cancers (Bilanges and Stokoe, 2007), while Cell 166, 963–976, August 11, 2016 ª 2016 Elsevier Inc. 963 enforced expression of certain translation factors transforms rodent fibroblasts and promotes tumorigenesis (Wendel et al., 2004).”
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?
Corradetti, M. N., & Guan, K.-L. (2006) · Oncogene · doi:10.1038/sj.onc.1209885 · Cited by 386
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
Graff, J. R., Konicek, B. W., Vincent, T. M., Lynch, R. L., Monteith, D., Weir, S. N., Schwier, P., Capen, A., Goode, R. L., Dowless, M. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32044 · Cited by 380
Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging
Castilho, R. M., Squarize, C. H., Chodosh, L. A., Williams, B. O., & Gutkind, J. S. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.06.017 · Cited by 371
“Based on recent studies supporting that the unconventional protein kinase mTOR represents a direct target of the Wnt pathway (Inoki et al., 2006), we also characterized the levels of the phosphorylated form of the mTOR downstream molecule, S6 (Wendel et al., 2004).”
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
“As well, in vivo overexpression of eIF4E within the B-cell compartment cooperates with c-Myc in lymphomagenesis as eIF4E counteractsMYCinduced apoptosis, a critical barrier to tumor formation (117, 118).”
BackgroundInfluentialSelf-citationTranslational Control in Cancer Etiology
Ruggero, D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012336 · Cited by 367
Oncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355
“Overexpression of eIF4E can transform cells as described above, and protect cells against apoptosis (Li et al. 2004; Wendel et al. 2004; Mamane et al. 2007; Wendel et al. 2007; Hsieh et al. 2010).”
BackgroundMartelli, A. M., Nyåkern, M., Tabellini, G., Bortul, R., Tazzari, P. L., Evangelisti, C., & Cocco, L. (2006) · Leukemia · doi:10.1038/sj.leu.2404245 · Cited by 342
Avdulov, S., Li, S., Michalek, V., Burrichter, D., Peterson, M., Perlman, D. M., Manivel, J. C., Sonenberg, N., Yee, D., Bitterman, P. B., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.024 · Cited by 340
Mavrakis, K. J., Wolfe, A. L., Oricchio, E., Palomero, T., de Keersmaecker, K., McJunkin, K., Zuber, J., James, T., Khan, A. A., Leslie, C. S., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2037 · Cited by 337
Self-citationTuberous sclerosis: a GAP at the crossroads of multiple signaling pathways
Kwiatkowski, D. J., & Manning, B. D. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi260 · Cited by 332
Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy
Graff, J. R., Konicek, B. W., Carter, J. H., & Marcusson, E. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5635 · Cited by 332
Bordeleau, M.-E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M. H., Wendel, H.-G., Brem, B., Greger, H., Lowe, S. W., Porco, J. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34753 · Cited by 332
Self-citationCommon corruption of the mTOR signaling network in human tumors
Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 332
Kern, L., Mittenbühler, M., Vesting, A., Ostermann, A., Wunderlich, C., & Wunderlich, F. (2018) · Cancers · doi:10.3390/cancers11010024 · Cited by 331
Bcl2 family proteins in carcinogenesis and the treatment of cancer
Frenzel, A., Grespi, F., Chmelewskij, W., & Villunger, A. (2009) · Apoptosis · doi:10.1007/s10495-008-0300-z · Cited by 331
Park, K.-R., Nam, D., Yun, H.-M., Lee, S.-G., Jang, H.-J., Sethi, G., Cho, S. K., & Ahn, K. S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.001 · Cited by 331
Hu, P., Han, Z., Couvillon, A. D., & Exton, J. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407700200 · Cited by 321
Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M.-C., Mills, G. B., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0361 · Cited by 319
Alexandre, J., Batteux, F., Nicco, C., Chéreau, C., Laurent, A., Guillevin, L., Weill, B., & Goldwasser, F. (2006) · International Journal of Cancer · doi:10.1002/ijc.21685 · Cited by 310
A Hypoxia-Controlled Cap-Dependent to Cap-Independent Translation Switch in Breast Cancer
Braunstein, S., Karpisheva, K., Pola, C., Goldberg, J., Hochman, T., Yee, H., Cangiarella, J., Arju, R., Formenti, S. C., & Schneider, R. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.10.019 · Cited by 308
Kentsis, A., Topisirovic, I., Culjkovic, B., Shao, L., & Borden, K. L. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406927102 · Cited by 305
Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 304
Integration of EGFR inhibitors with radiochemotherapy
Nyati, M. K., Morgan, M. A., Feng, F. Y., & Lawrence, T. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1953 · Cited by 304
Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302
Self-citationAntileukemic activity of rapamycin in acute myeloid leukemia
Récher, C., Beyne-Rauzy, O., Demur, C., Chicanne, G., Dos Santos, C., Mas, V. M.-D., Benzaquen, D., Laurent, G., Huguet, F., & Payrastre, B. (2005) · Blood · doi:10.1182/blood-2004-06-2494 · Cited by 296
mTORC1 promotes survival through translational control of Mcl-1
Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804821105 · Cited by 285
Self-citationPourdehnad, M., Truitt, M. L., Siddiqi, I. N., Ducker, G. S., Shokat, K. M., & Ruggero, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310230110 · Cited by 286
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
Jiang, Y., Ortega-Molina, A., Geng, H., Ying, H.-Y., Hatzi, K., Parsa, S., McNally, D., Wang, L., Doane, A. S., Agirre, X., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0975 · Cited by 278
Self-citationThe Splicing Factor SF2/ASF Regulates Translation Initiation by Enhancing Phosphorylation of 4E-BP1
Michlewski, G., Sanford, J. R., & Cáceres, J. F. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.013 · Cited by 277
The plasticity of mRNA translation during cancer progression and therapy resistance
Fabbri, L., Chakraborty, A., Robert, C., & Vagner, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00380-y · Cited by 276
The Organizing Principles of Eukaryotic Ribosome Recruitment
Pelletier, J., & Sonenberg, N. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111042 · Cited by 271
Self-citationRole of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Uddin, S., Hussain, A. R., Siraj, A. K., Manogaran, P. S., Al-Jomah, N. A., Moorji, A., Atizado, V., Al-Dayel, F., Belgaumi, A., El-Solh, H., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016907 · Cited by 262
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W., Kempf, C. R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., et al. (2011) · Leukemia · doi:10.1038/leu.2011.66 · Cited by 261
A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL)
Mavrakis, K. J., Van Der Meulen, J., Wolfe, A. L., Liu, X., Mets, E., Taghon, T., Khan, A. A., Setty, M., Rondou, P., Vandenberghe, P., et al. (2011) · Nature Genetics · doi:10.1038/ng.858 · Cited by 261
Self-citation
Metadata
- Authors
- Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W.
- Venue
- Nature
- Published
- 2004-03
- Volume
- 428
- Issue
- 6980
- Pages
- 332-337
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2065825082
- Cited by
- 951
- References
- 32
- FWCI
- 29.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.